Nathan Staff, MD
Neurology · Rochester, MNNPI 1730168915
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $69 of the $98 with a category attached, or 70.8%. Argenx US, Inc. accounts for 60.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $59 and has fallen 82.1% since, to $10 in 2025. That places this record below the midpoint for neurology clinicians in MN, where the typical reported total is $117.
Across 3 payments — averaging $32.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$59
- Tanabe Pharma America, Inc.$28
- Organon$10
Across 56 payments — averaging $4549.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mitsubishi Tanabe Pharma Development America, Inc.$117K
- AbbVie$65K
- Tanabe Pharma America, Inc.$62K
- Orion Corporation$11K
What the payments were for
- Food & beverage$6971%
- Education$2829%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 1 | $59 |
| Tanabe Pharma America, Inc. | 1 | $28 |
| Organon | 1 | $10 |
How this compares
$98 in reported general payments places this provider in the 45th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 28 | $437,253 |
| Riluzole | 11 | $1,386 |
| Scopolamine | 12 | $812 |
| Gabapentin | 14 | $513 |
Paid to pharmacies, not to this prescriber.
Other neurology in Rochester
- Alejandro RabinsteinRochester$305K
- Sean PittockRochester$231K
- Wolfgang SingerRochester$128K
- Ronald PetersenRochester$126K
- Partha GhoshRochester$121K
- Eoin FlanaganRochester$55K
- Keith CoffmanRochester$24K
- Igal MirmanRochester$18K
- P James DyckRochester$17K
- Suresh KotagalRochester$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.